Fairmount Funds Management LLC 13F Holdings · Q2 2026
Fairmount Funds Management LLC reported 12 securities worth $1.51B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ORKA (23.31%), DNTH (16.35%), DMRA (14.98%). Among its top 25 positions this quarter: 1 new, 1 added, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ORKA | ORUKA THERAPEUTICS INC | $352.6M | 23.31% | 3.7M | Hold |
| 2 | DNTH | DIANTHUS THERAPEUTICS INC | $247.3M | 16.35% | 2.5M | Hold |
| 3 | DMRA | DAMORA THERAPEUTICS INC | $226.6M | 14.98% | 8.7M | Hold |
| 4 | COGT | COGENT BIOSCIENCES INC | $213.0M | 14.08% | 5.5M | Hold |
| 5 | JBIO | JADE BIOSCIENCES INC | $101.2M | 6.69% | 4.6M | Hold |
| 6 | ELVN | ENLIVEN THERAPEUTICS INC | $94.2M | 6.22% | 1.9M | Hold |
| 7 | VRDN | VIRIDIAN THERAPEUTICS INC | $93.5M | 6.18% | 5.1M | Added |
| 8 | ZBIO | ZENAS BIOPHARMA INC | $59.9M | 3.96% | 2.4M | Hold |
| 9 | CBIO | CRESCENT BIOPHARMA INC. | $49.5M | 3.27% | 2.7M | Hold |
| 10 | APGE | APOGEE THERAPEUTICS INC | $39.6M | 2.62% | 298,647 | Hold |
| 11 | FTH | FAETH THERAPEUTICS INC | $18.1M | 1.19% | 722,020 | New |
| 12 | IKT | INHIBIKASE THERAPEUTICS INC | $17.5M | 1.16% | 8.6M | Hold |
| 13 | SYRE | SPYRE THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR